Figure 4

Co-treatment of NSCLC cell lines affects ERK1/2 and AKT signalling. (A) Cells were treated with 5 µM erlotinib (E), 10 µM pitavastatin (P) or fluvastatin (F) alone or in combination with 5 µM erlotinib for 72 h. β-actin was used as loading control, one of two replicate blots is shown. (B) Quantification of band intensities from (A) by densitometric analysis via ImageJ using the GelAnalyzer plugin as described41. Data represent arithmetic mean of three technical quantification replicates ± SD. F, fluvastatin; P, pitavastatin.